PLGA and PLCL EFs exhibit sustained-delivery of ACV through one month. EFs exhibit high ACV encapsulation efficiency and in vitro biocompatibility. EFs serve as both physical and chemical barriers to HSV-2 infection. Potent in vitro efficacy is provided against HSV-2 infection for all formulations. HSV-2 protection is independent of administration times within one month.